{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:27:47Z","timestamp":1777699667263,"version":"3.51.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.endonu.2010.03.008","type":"journal-article","created":{"date-parts":[[2010,5,7]],"date-time":"2010-05-07T10:39:17Z","timestamp":1273228757000},"page":"210-219","source":"Crossref","is-referenced-by-count":10,"title":["Avances en el tratamiento de la hipercolesterolemia"],"prefix":"10.1016","volume":"57","author":[{"given":"Juan F.","family":"Ascaso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endonu.2010.03.008_bib1","first-page":"410","article-title":"High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies","volume":"341","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.endonu.2010.03.008_bib2","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2010.03.008_bib3","first-page":"89","article-title":"The independent relationship between triglycerides and coronary heart disease","volume":"5","author":"Morrison","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.endonu.2010.03.008_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.endonu.2010.03.008_bib5","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.endonu.2010.03.008_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1575-0922(08)70642-9","article-title":"El laboratorio cl\u00ednico y las dislipemias","volume":"55","author":"Mendez","year":"2008","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.endonu.2010.03.008_bib7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1126\/science.1125884","article-title":"Biomedicine. Lowering LDL\u2013not only how low, but how long?","volume":"311","author":"Brown","year":"2006","journal-title":"Science."},{"key":"10.1016\/j.endonu.2010.03.008_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib9","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1210\/jc.86.10.4926","article-title":"Genetic diagnosis of Familial hypercholesterolemia in a South European outbreed population: Influence of LDL receptor gene mutations on treatment response to simvastatin in total, LDL and HDL cholesterol","volume":"86","author":"Chaves","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2010.03.008_bib10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0026-0495(93)90066-W","article-title":"The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism","volume":"42","author":"Carmena","year":"1993","journal-title":"Metabolism"},{"key":"10.1016\/j.endonu.2010.03.008_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10557-008-6113-z","article-title":"Effects of statins on high-density lipoprotein: a potential contribution to cardiovascular benefit","volume":"22","author":"McTaggart","year":"2008","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.endonu.2010.03.008_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/VHRM.S3662","article-title":"Efficacy and safety of rosuvastatin in the management of dyslipidemia","volume":"5","author":"Rubba","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.endonu.2010.03.008_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyo\u02c7r\u00e4l\u00e4","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endonu.2010.03.008_bib14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib15","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. The CARE Investigators","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.endonu.2010.03.008_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.endonu.2010.03.008_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"10 Suppl","key":"10.1016\/j.endonu.2010.03.008_bib18","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.endonu.2010.03.008_bib20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(96)05190-2","article-title":"Statins do more than just lower cholesterol","volume":"348","author":"Vaughan","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.endonu.2010.03.008_bib21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00041433-199712000-00005","article-title":"Stabilization of atherosclerotic plaque during lipid lowering","volume":"8","author":"M\u00fcller-Wieland","year":"1997","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.endonu.2010.03.008_bib22","first-page":"843","article-title":"HMG-CoA reductase inhibitors: a look back and a look ahead","volume":"8","author":"Davignon","year":"1992","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib23","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/01.ATV.19.2.187","article-title":"Systematic review on the risk and benefit of different cholesterol-lowering interventions","volume":"19","author":"Bucher","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.endonu.2010.03.008_bib26","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib27","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib28","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2010.03.008_bib29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2010.03.008_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib31","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of very high-intensity statin therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2010.03.008_bib33","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2010.03.008_bib34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3949\/ccjm.73.10.937","article-title":"Coronary atherosclerosis can regress with very intensive statin therapy","volume":"73","author":"Sipahi","year":"2006","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib35","doi-asserted-by":"crossref","first-page":"69F","DOI":"10.1016\/j.amjcard.2005.06.028","article-title":"Safety of high-dose atorvastatin therapy","volume":"96","author":"Waters","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/0002-9149(62)90328-4","article-title":"Coronary atherosclerosis and myocardial infarction in Kyushu, Japan, and Boston, Massachusetts","volume":"10","author":"Gore","year":"1962","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9149(77)80197-5","article-title":"Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: incidence of myocardial infarction and death from coronary heart disease","volume":"39","author":"Robertson","year":"1977","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib38","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/CIRCULATIONAHA.107.694117","article-title":"Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival","volume":"116","author":"Leeper","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.endonu.2010.03.008_bib40","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2008.06.037","article-title":"Statin, low-density lipoprotein cholesterol, and risk of cancer","volume":"52","author":"Alsheikh-Ali","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/bmj.308.6925.373","article-title":"Assessing possible hazards of reducing serum cholesterol","volume":"308","author":"Law","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.endonu.2010.03.008_bib42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.endonu.2010.03.008_bib43","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70mg\/dl. Lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2010.03.008_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1507\/endocrj.K05-098","article-title":"Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia","volume":"54","author":"Yamakawa","year":"2007","journal-title":"Endocr J"},{"key":"10.1016\/j.endonu.2010.03.008_bib46","first-page":"733","article-title":"Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors","volume":"3","author":"Bays","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.endonu.2010.03.008_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1253\/circj.70.14","article-title":"Cross-over trial of intensive monotherapy with atorvastatin and combined therapy with atorvastatin and colestimide for japanese familial hypercholesterolemia","volume":"70","author":"Tasaki","year":"2006","journal-title":"Circ J"},{"issue":"suppl","key":"10.1016\/j.endonu.2010.03.008_bib48","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/eurheartj\/ehp399","article-title":"Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin","volume":"31","author":"Chapman","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endonu.2010.03.008_bib50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.endonu.2010.03.008_bib51","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib52","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1172\/JCI27160","article-title":"Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid","volume":"115","author":"Pike","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.endonu.2010.03.008_bib53","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.endonu.2010.03.008_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacl.2009.02.009","article-title":"Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study","volume":"3","author":"Insull","year":"2009","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.endonu.2010.03.008_bib55","first-page":"90","article-title":"Efficacy and safety profile of coadministered ER niacin\/laropiprant and simvastatin in dyslipidaemia","volume":"16","author":"Gleim","year":"2009","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib56","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib57","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib58","unstructured":"US National Institutes of Health. Treatment of HDL to reduce the incidence of vascular events (HPS2-THRIVE). Clinicaltrials.gov, 2010 NCT00461630. [Consultado 15\/1\/2010]. Disponible en: http:\/\/www.clinicaltrials.gov\/ct\/show"},{"key":"10.1016\/j.endonu.2010.03.008_bib59","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1185\/030079907X188062","article-title":"Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia","volume":"23","author":"Kalogirou","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.endonu.2010.03.008_bib60","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4065\/81.12.1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hipercholesterolemia: The VYTAL study","volume":"81","author":"Goldberg","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.endonu.2010.03.008_bib61","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2169\/internalmedicine.47.1099","article-title":"Ezetimibe, a selective inhibitor of the transport of cholesterol","volume":"47","author":"Miura","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib62","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJMsr0900910","article-title":"Premature release of data from clinical trials of ezetimibe","volume":"361","author":"Califf","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib63","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjcard.2009.05.020","article-title":"Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force\/Texas Coronary Atherosclerosis Prevention Study)","volume":"104","author":"Cui","year":"2009","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"10.1016\/j.endonu.2010.03.008_bib64","doi-asserted-by":"crossref","first-page":"58B","DOI":"10.1016\/j.amjcard.2008.02.039","article-title":"Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk","volume":"101","author":"Brown","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib65","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1185\/03007990802363198","article-title":"Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey","volume":"24","author":"Zhang","year":"2008","journal-title":"Curr Med Res Opinion"},{"key":"10.1016\/j.endonu.2010.03.008_bib66","doi-asserted-by":"crossref","first-page":"60B","DOI":"10.1016\/S0002-9149(98)00040-X","article-title":"Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia","volume":"81","author":"Ellen","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.endonu.2010.03.008_bib67","unstructured":"The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010; Mar 18. [Epub ahead of print]"},{"key":"10.1016\/j.endonu.2010.03.008_bib68","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2008-0269","article-title":"A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia","volume":"93","author":"Blesa","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endonu.2010.03.008_bib69","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endonu.2010.03.008_bib70","unstructured":"Ascaso JF, Real JT, Arbona C. T\u00e9cnicas de tratamiento poco frecuentes o en fase de investigaci\u00f3n (plasmaf\u00e9resis, terapia g\u00e9nica) en las dislipemias. En: Manual del Residente de Endocrinolog\u00eda y Nutrici\u00f3n. ISBN 978-84-692-1347-2. Madrid, SEEN, 2009. p. 969\u201381."},{"key":"10.1016\/j.endonu.2010.03.008_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.endonu.2010.03.008_bib72","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.endonu.2010.03.008_bib73","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"}],"container-title":["Endocrinolog\u00eda y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092210000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1575092210000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T08:57:59Z","timestamp":1544518679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1575092210000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1575092210000537"],"URL":"https:\/\/doi.org\/10.1016\/j.endonu.2010.03.008","relation":{},"ISSN":["1575-0922"],"issn-type":[{"value":"1575-0922","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}